Print Share Email Send Email Your Name (required) ! Example: John Doe Email Address (required) ! Error: Please enter a valid sender email address. Example: firstname.lastname@example.org CC Me Recipient Email Address (required) ! Separate multiple email address with semi-colons (up to 5). Subject Subject for your email. Message (Maximum characters: 1,000) Error: Please enter your name Error: Please enter your email address Error: Please enter a valid recipient email address. Example:email@example.com Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Hinohara T, Mechanick JI. Hinohara T, & Mechanick J.I. Hinohara, Tomoya, and Jeffrey I. Mechanick. Subgroup Analysis of DAPA-HF Suggests that Dapagliflozin is Effective and Safe in Patients with Heart Failure, Regardless of Age. Hurst's the Heart Updates, 19 December 2019. McGraw-Hill, 2019. AccessCardiology. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=514994§ionid=234854630APA Citation Hinohara T, Mechanick JI. Hinohara T, & Mechanick J.I. Hinohara, Tomoya, and Jeffrey I. Mechanick. (2019). Subgroup analysis of dapa-hf suggests that dapagliflozin is effective and safe in patients with heart failure, regardless of age. Fuster V. Fuster V Fuster, Valentin. Hurst's the heart updates. McGraw-Hill. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=514994§ionid=234854630.MLA Citation Hinohara T, Mechanick JI. Hinohara T, & Mechanick J.I. Hinohara, Tomoya, and Jeffrey I. Mechanick. "Subgroup Analysis of DAPA-HF Suggests that Dapagliflozin is Effective and Safe in Patients with Heart Failure, Regardless of Age." Hurst's the Heart Updates Fuster V. Fuster V Fuster, Valentin. McGraw-Hill, 2019, https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=514994§ionid=234854630. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Subgroup Analysis of DAPA-HF Suggests that Dapagliflozin is Effective and Safe in Patients with Heart Failure, Regardless of Age by Tomoya Hinohara, Jeffrey I. Mechanick Listen + +Update to Chapter 70: The Diagnosis and Management of Chronic Heart Failure Study Summary + +The DAPA-HF trial1 demonstrated that the sodium-glucose cotransporter-2 (SGLT2) inhibitor, dapagliflozin, reduced mortality and hospitalizations for heart failure (HF) in patients with HF with reduced ejection fraction (HFrEF) irrespective of diabetes status. Given concerns regarding the safety and efficacy of dapagliflozin in the elderly, the investigators conducted a subgroup analysis2 to examine the effects of this drug according to age. Patients receiving optimal medical therapy for symptomatic HF (left ventricular EF ≤40%) were included. Patients were randomly assigned to receive 10 mg of dapagliflozin daily or placebo (n = 4,744). Patient ages were as follows: 636 (13.4%) were <55 years; 1,242 (26.2%) were 55–64 years; 1,717 (36.2%) were 65–74 years; and 1,149 (24.2%) were ≥75 years. +The incidence of the primary composite outcome of first episode of worsening HF (defined as hospitalization or an urgent care visit for HF) or cardiovascular death was lower in the dapagliflozin group than in the placebo group for each age range. Hazard ratios were as follows: 0.87 (95% CI 0.6–1.28) for <55 years; 0.71 (95% CI 0.55–0.93) for 55–64 years; 0.76 (95% CI 0.61–0.95) for 65–74 years; and 0.68 (95% CI 0.53–0.88) for ≥75 years (P for interaction = 0.76). There were no differences in treatment discontinuation or adverse events — including volume depletion, renal dysfunction, and hypoglycemia — between the treatment groups for each age range. Commentary + +Study Strengths: This study is the first evaluation of the safety and efficacy of dapagliflozin according to age in patients with established HF regardless of diabetes status. +Study Limitations: This is a post hoc subgroup analysis and, therefore, susceptible to selection bias due to lack of randomization by age group. The DAPA-HF trial was not powered to detect differences by age. Additionally, the age categories were chosen arbitrarily. +Next Steps/Clinical Perspective: The benefits and safety of dapagliflozin in different age groups are not known, and there is concern that the drug might be poorly tolerated in the elderly owing to advanced age and polypharmacy2. This subgroup analysis provides evidence that dapagliflozin is efficacious regardless of age and thus associated with improved outcomes in the HF population independent of age and diabetes status. Furthermore, there were no significant differences in tolerability or safety between dapagliflozin and placebo when stratified by age, including in the elderly. References + + +1. +McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. doi: 10.1056/NEJMoa1911303. +2. +Martinez, F. A. et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation doi: 10.1161/CIRCULATIONAHA.119.044133. +3. +Sztramko, R., Chau, V., & Wong, R. Adverse drug events and associated factors in heart failure therapy among the very elderly. Can. Geriatr. J.14:79–92 (2011).